Crescent Biopharma (FRA:C68) Common Stock: €0.02 Mil (As of Mar. 2026)


FRA:C68 Crescent Biopharma Inc FRA:C68
18 GF Score
Price €14.60
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma Common Stock?

Crescent Biopharma FRA:C68 18 Common Stock is €0.02 Mil as of Mar. 2026. GuruFocus rates FRA:C68 with a GF Score™ of 18/100. The stock has 2 warning signs investors should review.

Crescent Biopharma's quarterly common stock increased from Sep. 2025 (€0.01 Mil) to Dec. 2025 (€0.02 Mil) but then stayed the same from Dec. 2025 (€0.02 Mil) to Mar. 2026 (€0.02 Mil).

Crescent Biopharma's annual common stock increased from . 20 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) and increased from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€0.02 Mil).

Crescent Biopharma Common Stock Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Common Stock Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
Common Stock
0.00 0.02

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial 0.00 0.01 0.01 0.02 0.02
FRA:C68
18GF Score
Crescent Biopharma Inc FRA:C68
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €0.02 Mil mean?
Crescent Biopharma (FRA:C68) has a Common Stock of €0.02 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Crescent Biopharma and its competitors.
Is Crescent Biopharma's Common Stock too high?
Crescent Biopharma's current Common Stock is €0.02 Mil. Overall, Crescent Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Common Stock compare to KYTX and ZURA?
Crescent Biopharma's Common Stock of €0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Crescent Biopharma and its competitors. Crescent Biopharma's current Common Stock is €0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (FRA:C68) has a current Common Stock of €0.02 Mil. The current Common Stock is €0.02 Mil. Crescent Biopharma's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Crescent Biopharma (FRA:C68), the current Common Stock is €0.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges CBIO:USA
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
18GF Score

Get the complete analysis for FRA:C68

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.60
Price